NEW YORK, Feb. 10, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global antibiotics market size is estimated to grow by USD 18.22 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of over 5.9% during the forecast period. Rising prevalence of infectious diseases is driving market growth, with a trend towards strategic alliances and mergers and acquisitions. However, high research and development costs and long development cycles poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Flynn Pharma Ltd., GlaxoSmithKline Plc, Incepta Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Mayne Pharma Group Ltd., Melinta Therapeutics LLC, Merck KGaA, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd..
Technavio has announced its latest market research report titled Global Antibiotics Market 2025-2029
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF
|
Antibiotics Market Scope |
|
|
Report Coverage |
Details |
|
Base year |
2024 |
|
Historic period |
2019 – 2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
|
Market growth 2025-2029 |
USD 18.22 billion |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023 (%) |
5.5 |
|
Regional analysis |
Asia, North America, Europe, and Rest of World (ROW) |
|
Performing market contribution |
Asia at 42% |
|
Key countries |
US, China, Japan, Canada, India, South Korea, Germany, France, Brazil, and Indonesia |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Flynn Pharma Ltd., GlaxoSmithKline Plc, Incepta Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Mayne Pharma Group Ltd., Melinta Therapeutics LLC, Merck KGaA, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market Driver
Strategic alliances through licensing and collaboration agreements play a significant role in the antibiotics market. These partnerships enable co-development and commercialization of drugs in various regions, leveraging the technical expertise and regulatory experience of both parties. Co-development agreements reduce liability costs and attract venture investments. Mergers and acquisitions (M&A) expand market penetration and enhance product portfolios. Smaller companies benefit from these agreements for drug development. In 2023, Abbott expanded registration for access antibiotics and antifungals in India, as per the World Health Organization’s essential medicines list, driving market growth.
The antibiotics market is experiencing significant growth due to the rising incidence of bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. Antibacterial drugs, such as broad-spectrum and narrow-spectrum antibiotics, are in high demand to combat these bacterial strains. Companies like GlaxoSmithKline, Merck, Melinta Therapeutics, Janssen, and others are leading the charge in developing new antibiotics to address antibiotic resistance. Bacterial infections, including chronic diseases and hospital-acquired diseases, are a major concern for healthcare providers. Gram positive and gram-negative bacteria, such as Staphylococcus aureus and E. Coli, are common causes of these infections. Companies like Biocidium Biopharmaceuticals, Blacksmith Medicines, and Bugworks Research are focusing on developing new antibiotics to target these bacterial strains. Definitive Healthcare reports that clinical trials for new antibiotics are ongoing for Cephalosporin, Penicillin, Macrolides, Tetracycline, and other antibiotics. Antimicrobial resistance is a growing concern, with strains such as Selmod49, Sinovent, and Spero Therapeutics’ microbe XP-841 showing resistance to current antibiotics. Companies like Wockhardt, Xediton Pharmaceuticals, and Helperby Therapeutics are working on developing new antibiotics to address this issue. In conclusion, the antibiotics market is growing due to the increasing incidence of bacterial infections and the need for new antibiotics to combat antibiotic resistance. Companies are investing in research and development to bring new antibiotics to market, including those targeting gram positive and gram-negative bacteria.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!
Market Challenges
The misuse and overuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant challenge to human health. This issue arises due to the inappropriate prescription of antibiotics by healthcare professionals and incorrect usage by individuals, coupled with the widespread use of antibiotics in livestock farming. The accumulation of antibiotics in the body contributes to the development of resistance, rendering commonly used antibiotics ineffective against these microbes. Consequently, the market growth for antibiotics is negatively impacted as patients no longer accept ineffective treatments, leading to decreased demand for these drugs during the forecast period.
The antibiotics market faces significant challenges from the rising threat of antimicrobial resistance. Companies like Biocidium Biopharmaceuticals, Blacksmith Medicines, and Bristol Myers Squibb are developing new antibiotics to combat this issue. Definitive Healthcare data shows that chronic diseases and hospital-acquired diseases require continuous treatment with antibiotics, including Cephalosporin, Penicillin, Macrolides, Tetracycline, and their derivatives like Suifonamides, Fluoroquinolones, and Aminoglycosides. However, the development of new antibiotics is complex and costly. Companies like Helperby Therapeutics, Madam Therapeutics, and Spero Therapeutics are focusing on innovative approaches, such as repurposing existing drugs or using the parenteral route for administration. Retail pharmacies play a crucial role in delivering these essential medicines to patients, treating infections like skin infections, urinary tract infections, septicemia, gastrointestinal infections, and respiratory infections. Companies like Bugworks Research, Pattern Bioscience, Xediton Pharmaceuticals, and Selvita are also contributing to the antibiotics pipeline. The future of antibiotics lies in collaboration, innovation, and a commitment to addressing antimicrobial resistance.
Discover how AI is revolutionizing market trends- Get your access now!
Segment Overview
This antibiotics market report extensively covers market segmentation by
Product
Broad-spectrum Antibiotics
Narrow-spectrum Antibiotics
Route Of Administration
Intravenous
Oral
Others
Geography
Asia
North America
Europe
Rest Of World (ROW)
1.1 Broad-spectrum antibiotics- Broad-spectrum antibiotics are widely used in the medical industry due to their effectiveness against various gram-positive and gram-negative microorganisms. These drugs offer a better treatment option in cases where bacteria do not respond to narrow-spectrum antibiotics or when the infecting agent is not identified. Commonly used broad-spectrum antibiotics include amoxicillin, levofloxacin, gatifloxacin, streptomycin, tetracycline, and chloramphenicol. The market for broad-spectrum antibiotics is growing due to the increasing prevalence of bacterial infections, particularly in underdeveloped and developing regions with poor sanitation and lifestyle. The affordability of generic broad-spectrum antibiotics in these regions also contributes to the market’s growth. Despite their benefits, the overuse of broad-spectrum antibiotics can lead to antibiotic resistance, making it crucial to use these drugs judiciously.
Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics
Research Analysis
The antibiotics market encompasses a wide range of antibacterial drugs used to treat various bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. Antibiotics work by inhibiting the growth of bacteria or killing them outright. Broad-spectrum antibiotics, such as cephalosporins and penicillin, target a wide range of bacterial strains, while narrow-spectrum antibiotics like tetracyclines, macrolides, sulfonamides, fluoroquinolones, and aminoglycosides, are more specific to certain types. Clinical trials are ongoing to develop new antibiotics to combat antibiotic resistance, a growing concern in healthcare. Common bacterial infections treated with antibiotics include skin infections, urinary tract infections, septicemia, and gastrointestinal and respiratory infections. Some commonly used antibiotics include Cephalosporin, Penicillin, Macrolides, Tetracycline, and their derivatives. Definitive Healthcare provides comprehensive data and insights on the antibiotics market, including pipeline analysis, clinical trials, and market trends.
Market Research Overview
Antibiotics are essential medicines used to treat bacterial infections caused by pathogenic bacteria, including multi-drug resistant strains. Antibacterial drugs come in various forms, such as broad-spectrum and narrow-spectrum antibiotics, each targeting specific bacterial strains. The rise of antibiotic resistance poses a significant challenge to the effective treatment of bacterial infections, leading to increased research and development in the antibiotics market. Bacterial infections can affect various parts of the body, including chronic diseases and hospital-acquired diseases. Common infections include skin infections, urinary tract infections, septicemia, gastrointestinal infections, and respiratory infections. Antibiotics work by disrupting the bacterial cell wall or interfering with the bacterial protein synthesis. Common classes of antibiotics include Cephalosporin, Penicillin, Macrolides, Tetracycline, Suifonamides, Fluoroquinolones, and Aminoglycosides. The antibiotics market is dynamic, with numerous companies investing in clinical trials for new antibacterial drugs. Definitive Healthcare reports that key players include GlaxoSmithKline, Merck, Melinta Therapeutics, Janssen, and several other companies such as Biocidium Biopharmaceuticals, Blacksmith Medicines, and Spero Therapeutics. Antibiotics can be administered through various routes, including parenteral route and retail pharmacies. The antibiotics market is continuously evolving to address the challenge of antibiotic resistance, with new companies and innovations emerging regularly.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Product
Broad-spectrum Antibiotics
Narrow-spectrum Antibiotics
Route Of Administration
Intravenous
Oral
Others
Geography
Asia
North America
Europe
Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
